What Anafronil Treats: Main Uses and Benefits

This medication is commonly used to address the symptomatic burden of Obsessive-Compulsive Disorder (OCD) in adults and children (10 years and older). It helps ease the intensity of intrusive, unwanted thoughts and may assist in easing the symptomatic burden of repetitive, intentional rituals. This medication is also relevant for easing symptoms in severe mood conditions (like Major Depressive Disorder), Panic Disorder, and specialized conditions like Cataplexy associated with Narcolepsy.

Anafronil is applied in clinical settings marked by severe, long-term mood imbalances or when a patient requires additional symptomatic support for conditions characterized by periods of heightened symptoms. The therapeutic benefit contributes to easing the overall symptom load and may support patients in maintaining functional stability when symptoms interfere with daily functioning. It is also used in therapeutic contexts requiring support for persistent discomfort, such as neuropathic pain and certain types of chronic headache, and is relevant for easing symptoms related to physical discomfort.

“The medication supports patients during difficult episodes by easing distress and may help patients cope more steadily with symptom fluctuations.”

---

Quick Fact: Relief for Obsessive and Compulsive Manifestations

Anafronil is commonly used across therapeutic domains involving heightened physiological activity and helps address symptom clusters that become more disruptive during flare-ups, offering symptomatic relief that supports general well-being during symptomatic phases.

Population Eligibility Rules for Anafronil (Clomipramine)

Official regulatory guidelines strictly define the populations permitted, restricted, or prohibited from using Anafronil, based on absolute contraindications and physiological status.

Eligibility Status	Key Regulatory Criteria
Use is Contraindicated (Must Not Use)	Patients with a recent myocardial infarction (MI), certain cardiac conduction disorders (e.g., heart block), severe liver disease, narrow-angle glaucoma, or untreated urinary retention. Use is also prohibited if the patient has a known hypersensitivity to clomipramine or other tricyclic antidepressants (TCAs), or is taking a Monoamine Oxidase Inhibitor (MAOI) [Source 1.2, 2.3].
Use is Conditional or Restricted	Older adults (65 years and older) require close monitoring. Patients with renal impairment or pre-existing cardiovascular insufficiency should use the medicine with caution [Source 1.8, 2.7]. Use during pregnancy and lactation is generally not recommended [Source 1.7].
Approved Age Group	The medicine is approved for Obsessive-Compulsive Disorder (OCD) in patients 10 years of age and older. Use is not established below this age threshold. For non-OCD indications, use is not recommended in adolescents under 18 [Source 1.6, 1.7].

Interactions with other medicines and products

The official regulatory profile for Clomipramine Hydrochloride (Anafronil) establishes mandatory restrictions and documented risks when co-administered with specific substances or classes of medicines. This information is derived exclusively from government prescribing labels.

---

Regulatory Restrictions

Category	Restriction/Outcome
Monoamine Oxidase Inhibitors (MAOIs)	Contraindicated. Must not be co-administered. A mandatory washout period of at least 14 days is required when switching between Anafronil and a non-reversible MAOI.
QTc-Prolonging Agents	Contraindicated with drugs like Pimozide and Thioridazine due to the official risk of serious cardiac arrhythmias.

---

Documented Pharmacokinetic and Pharmacodynamic Risks

Co-administration with potent CYP2D6 inhibitors (e.g., Fluoxetine) and CYP1A2 inhibitors (e.g., Fluvoxamine) is documented to increase the plasma concentrations and systemic exposure of Anafronil and its metabolite. This is a pharmacokinetic interaction requiring cautious use.

Simultaneous use with other serotonergic agents (e.g., Triptans, SSRIs) is associated with an increased regulatory risk of Serotonin Syndrome (a pharmacodynamic effect). Additive CNS depression is documented when Anafronil is combined with alcohol or other CNS depressants. Furthermore, regulatory documents note that elderly patients are documented to have significantly higher steady-state plasma concentrations, increasing the potential for interaction severity.

How Anafranil Works

Anafranil (clomipramine) influences central nervous system function through a dual biological mechanism involving the inhibition of key chemical reuptake transporters and the antagonism of various neuroreceptors.

Inhibition of Serotonin and Norepinephrine Reuptake Transporters

The primary action involves the drug and its active metabolite binding to the reuptake transporters for the neurotransmitters serotonin ( 5-HT) and norepinephrine ( NE). By blocking the reabsorption mechanisms of the Serotonin Transporter (SERT) and the Norepinephrine Transporter (NET), clomipramine causes a sustained increase in the concentration of these signaling chemicals in the synaptic cleft. This leads to altered neuronal signaling patterns and subsequent long-term changes in receptor sensitivity.

Antagonism of Peripheral and Central Receptors

In addition to its reuptake inhibition, the drug acts as an antagonist (blocker) at several other cellular communication sites, including mathbfH1 (histamine), mathbfM1 (muscarinic cholinergic), and mathbfalpha1 (adrenergic) receptors. This broad receptor blockade affects various systems, resulting in physiological consequences such as changes in levels of arousal and alterations to autonomic nervous system activity.

How Anafronil is Used: Official Administration Guidelines

Anafronil (Clomipramine Hydrochloride) is administered exclusively via the oral route using capsules or tablets. The administration follows a structured protocol requiring careful adjustment over time to establish a stable maintenance dose.

---

Official Dosing and Frequency Patterns

The initiation of treatment requires a gradual dose increase, known as titration, beginning with a low starting dose, such as 25 mg daily. The dosage is incrementally raised over several weeks until the therapeutic maintenance range is reached, typically 100 mg to 150 mg daily for adults. The maximum daily dose for most adult indications is strictly capped at 250 mg.

Classification	Administration Principle
Route of Administration	Oral (via capsule or tablet)
Frequency Pattern	Once daily or in divided daily doses
Time of Day	Total daily dose may be taken as a single dose at bedtime

---

Administration Requirements and Adjustments

Administration of the medicine may be done with or without food, although initial doses are often suggested to be taken with meals for better tolerance. Tablets and capsules must be swallowed whole with water; specifically, sustained-release tablets must not be crushed or chewed to preserve their intended release characteristics.

Procedural adjustments are required for specific populations. Older adults typically start at a lower initial dose (e.g., 10 mg daily) and have a lower maximum daily limit, usually 75 mg to 100 mg. Furthermore, treatment is typically long-term, and cessation of the medicine must be accomplished via a gradual dose reduction (tapering) process, rather than abrupt discontinuation.

Research Evidence / Overview of Studies for Anafronil (Clomipramine)

---

Evidence for Use in Obsessive-Compulsive Disorder (OCD)

The research for clomipramine in Obsessive-Compulsive Disorder (OCD) is based primarily on short-term Randomized Controlled Trials (RCTs). These studies were conducted to examine how symptoms change over defined time intervals, typically lasting around 8 to 12 weeks. Researchers monitored changes in the intensity of both obsessive thoughts and compulsive behaviors using standardized tools, such as the Yale-Brown Obsessive Compulsive Scale (Y-BOCS).

In these trials, findings describe patterns observed in the studies where measurements of obsessive and compulsive symptom scores were reported in comparison to baseline. Some trials included a comparison group receiving an inactive control (placebo). There is limited information for long-term outcomes that explore sustained patterns or the prevention of symptom return (relapse prevention) over many months.

---

Evidence for Use in Major Depressive Disorder (MDD)

Clomipramine was studied for Major Depressive Disorder (MDD). The evidence structure includes older historical controlled trials and subsequent analyses. These studies explored symptom severity in patients with MDD, often focusing on outcomes reflecting daily functioning or activity level. The research examined symptom change using various rating scales, such as the Hamilton Depression Rating Scale (HDRS).

Findings describe patterns related to changes in mood symptom scores observed in some studies during the acute treatment period. However, evidence is limited when considering the availability of recent, large-scale RCTs that directly compare clomipramine against newer pharmacological options. Because the evidence base is primarily historical, certainty remains low for this evidence structure when evaluated against modern trial standards.

---

What is Still Uncertain About Anafronil Research

Several areas of uncertainty exist within the body of research for clomipramine. A key limitation is that evidence quality varies across studies, with many findings derived from historical trials that do not use current standardized trial methodologies. Additionally, comparative evidence is lacking in large-scale, modern trials against some of the newer agents widely used today. Finally, for most indications, there is limited information for long-term outcomes and functional stability.

Key Studies & References

1. NICE Guideline CG31: Obsessive-compulsive disorder and body dysmorphic disorder: treatment
2. Clomipramine for Obsessive-Compulsive Disorder - StatPearls (NIH)

Common questions about Anafronil (FAQ)

---

Q: What is the generic name for Anafranil?

According to official regulatory documents, the active ingredient in Anafranil is Clomipramine Hydrochloride. This is the recognized generic name for the medicine.

---

Q: Where in the brain does Anafranil work?

Official product information indicates that Anafranil influences specific behaviors through its effects on the central nervous system. Its primary action is understood to involve blocking the reabsorption (reuptake) of the chemical messengers serotonin (5 -HT) and norepinephrine ( NE), altering chemical signals in the brain.

---

Q: How quickly does Anafranil start working for OCD?

Regulatory information indicates that the onset of noticeable therapeutic effect may take several weeks. Clinical trials for Obsessive-Compulsive Disorder (OCD) typically lasted for 8 to 10 weeks to measure the drug's effectiveness.

---

Q: What should I do if I miss a dose of Anafranil?

Regulatory guidance specifies that if a dose is missed, it can be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Two doses should not be taken at the same time to make up for a single missed dose.

---

Q: What is the starting dose for Anafranil?

Official labeling states that treatment begins with a low daily dose, which is then gradually increased over time as directed by a healthcare professional. A lower initial dose is generally used for older adults, reflecting the need for cautious, individualized dosing.

---

Q: What are the storage requirements for Anafranil?

Anafranil must be stored at Controlled Room Temperature, which is typically between 20^circ and 25 C. The medicine must be kept in a tight, light-resistant container, as required by regulatory specifications for product stability.

Official Storage and Disposal Instructions

Anafranil (clomipramine hydrochloride) must be stored according to specific regulatory requirements to maintain product stability.

Requirement	Official Condition (Regulatory Basis)
Storage Temperature	Controlled Room Temperature (20^circ to 25 C / 68^circ to 77 F)
Protection	Protect from moisture; Dispense in a tight, light-resistant container.
Child Safety	Keep out of the sight and reach of children; use a child-resistant closure.
Disposal	Dispose of unused product according to local regulations, using drug take-back programs or authorized methods.

Storage outside the permitted range (15^circ to 30 C) is not recommended, and disposal via wastewater or household waste is generally prohibited unless following official household discard instructions (e.g., mixing with unappealing substances). The container specifications ensure the product is shielded from light and moisture.